To include your compound in the COVID-19 Resource Center, submit it here.

Ridaforolimus: Phase II data

An open-label, Canadian Phase II trial in 26 evaluable patients showed that once-daily 40 mg oral ridaforolimus for

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE